These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24619702)

  • 41. Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.
    Williams JA; Luke J; Langtry S; Anderson S; Hodgson CP; Carnes AE
    Biotechnol Bioeng; 2009 Aug; 103(6):1129-43. PubMed ID: 19408315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physiological effects of pH gradients on Escherichia coli during plasmid DNA production.
    Cortés JT; Flores N; Bolívar F; Lara AR; Ramírez OT
    Biotechnol Bioeng; 2016 Mar; 113(3):598-611. PubMed ID: 26301871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Designing expression plasmid vectors in E. coli.
    Balbás P
    Methods Mol Biol; 1997; 62():11-6. PubMed ID: 9108508
    [No Abstract]   [Full Text] [Related]  

  • 44. [Construction of vector plasmids for the Plectonema boryanum cyanobacterium and creation, on such basis, of the vector-host system].
    Samoĭlenko VA; Tsymbal NV; Syrchin SA; Mendzhul MI
    Mol Gen Mikrobiol Virusol; 2003; (3):33-8. PubMed ID: 12966925
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Purification of plasmids for gene therapy and DNA vaccination.
    Prazeres DM; Monteiro GA; Ferreira GN; Diogo MM; Ribeiro SC; Cabral JM
    Biotechnol Annu Rev; 2001; 7():1-30. PubMed ID: 11686041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.
    Egan MA; Megati S; Roopchand V; Garcia-Hand D; Luckay A; Chong SY; Rosati M; Sackitey S; Weiner DB; Felber BK; Pavlakis GN; Israel ZR; Eldridge JH; Sidhu MK
    Vaccine; 2006 May; 24(21):4510-23. PubMed ID: 16140439
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Main Features of DNA-Based Vectors for Use in Lactic Acid Bacteria and Update Protocols.
    Coelho-Rocha ND; Barroso FAL; Tavares LM; Dos Santos ESS; Azevedo V; Drumond MM; Mancha-Agresti P
    Methods Mol Biol; 2021; 2197():285-304. PubMed ID: 32827144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Production and purification of plasmid DNA vaccines: is there scope for further innovation?
    Xenopoulos A; Pattnaik P
    Expert Rev Vaccines; 2014 Dec; 13(12):1537-51. PubMed ID: 25308708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design of plasmid DNA constructs for vaccines.
    Montgomery DL; Prather KJ
    Methods Mol Med; 2006; 127():11-22. PubMed ID: 16988443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A host/plasmid system that is not dependent on antibiotics and antibiotic resistance genes for stable plasmid maintenance in Escherichia coli.
    Hägg P; de Pohl JW; Abdulkarim F; Isaksson LA
    J Biotechnol; 2004 Jul; 111(1):17-30. PubMed ID: 15196766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Issues for improving multiplasmid DNA vaccines for HIV-1.
    Muthumani K; Kudchodkar S; Zhang D; Bagarazzi ML; Kim JJ; Boyer JD; Ayyavoo V; Pavlakis GN; Weiner DB
    Vaccine; 2002 May; 20(15):1999-2003. PubMed ID: 11983262
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA vaccines: vector design, delivery, and antigen presentation.
    Feltquate DM
    J Cell Biochem Suppl; 1998; 30-31():304-11. PubMed ID: 9893284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A survey of drug resistance bla genes originating from synthetic plasmid vectors in six Chinese rivers.
    Chen J; Jin M; Qiu ZG; Guo C; Chen ZL; Shen ZQ; Wang XW; Li JW
    Environ Sci Technol; 2012 Dec; 46(24):13448-54. PubMed ID: 23215020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Plant-Based Transient Expression System for the Rapid Production of Malaria Vaccine Candidates.
    Boes A; Reimann A; Twyman RM; Fischer R; Schillberg S; Spiegel H
    Methods Mol Biol; 2016; 1404():597-619. PubMed ID: 27076325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flavivirus DNA Vaccine Design and Adjuvant Selection.
    Li L; Honda-Okubo Y; Petrovsky N
    Methods Mol Biol; 2021; 2183():405-422. PubMed ID: 32959256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new vector for heterologous gene expression in Escherichia coli with increased stability in the absence of antibiotic.
    Eguia FAP; Ramos HR; Kraschowetz S; Omote D; Ramos CRR; Ho PL; Carvalho E; Gonçalves VM
    Plasmid; 2018 Jun; 98():22-30. PubMed ID: 30193910
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequence-Modified Antibiotic Resistance Genes Provide Sustained Plasmid-Mediated Transgene Expression in Mammals.
    Lu J; Zhang F; Fire AZ; Kay MA
    Mol Ther; 2017 May; 25(5):1187-1198. PubMed ID: 28365028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two-Step Bacterial Artificial Chromosome (BAC) Engineering: Electroporation of Competent BAC Host Cells with the Recombinant Shuttle Vector.
    Heintz N; Gong S
    Cold Spring Harb Protoc; 2020 Apr; 2020(4):098079. PubMed ID: 32238593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Production of plasmid DNA for pharmaceutical use.
    Voss C
    Biotechnol Annu Rev; 2007; 13():201-22. PubMed ID: 17875478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of antibiotic-free selection system for safer DNA vaccination.
    Luke JM; Carnes AE; Williams JA
    Methods Mol Biol; 2014; 1143():91-111. PubMed ID: 24715283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.